Format

Send to

Choose Destination
Tumour Biol. 2007;28(5):264-72. Epub 2007 Oct 26.

Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients.

Author information

1
Medical Oncology Department and Laboratory of Experimental Oncology, Hospital Clínic, Barcelona, Spain. 33884jdd@comb.es

Abstract

OBJECTIVE:

It was the aim of this study to analyze the clinical value of the determination of serum S-100beta protein in high-risk melanoma patients.

PATIENTS AND METHODS:

Patients were tested for serum S-100beta protein by luminoimmunometric assay after melanoma surgical excision, before starting interferon-alpha2b and every 3 months thereafter, until treatment was completed.

RESULTS:

Ninety-seven patients were included in the study. Median follow-up was 62.9 months (range 32.7-87.4). High baseline S-100beta levels were associated with positive lymph node status (p = 0.02). High S-100beta levels (during therapy) showed a relation with positive lymph node status (p = 0.014), number of positive lymph nodes (p = 0.01), macroscopic lymph node involvement (p = 0.002) and second melanoma diagnosis at study entry (p = 0.001). By univariate analysis, high baseline S-100beta levels were associated with disease-free survival (p = 0.004) and overall survival (p = 0.0007). Similarly, high S-100beta levels during therapy were associated with disease-free survival (p < 0.0001) and overall survival (p < 0.0001). In the multivariate analysis, high S-100beta levels during therapy (hazard ratio 1.017, 95% CI 1.008-1.026; p < 0.0001) and high baseline S-100beta levels (hazard ratio 3.31, 95% CI 1.10-9.89; p = 0.032) were independent prognostic factors for overall survival when compared with low levels while on therapy and low baseline S-100beta levels, respectively.

CONCLUSIONS:

These results provide evidence of the clinical usefulness of serum S-100beta level determination in high-risk melanoma patients. S-100beta serum determination should be considered to be included in clinical trials that test adjuvant therapies in melanoma patients.

PMID:
17962723
DOI:
10.1159/000110424
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center